By Dr Lisa Stehno-Bittel – President and Founder of Likarda2025-03-26T08:00:30
Hormone replacement therapy has long been used to treat low hormone levels, but existing delivery methods struggle with poor adherence and inconsistent hormone delivery. Lisa Stehno-Bittel of Likarda and Charles Virden of VitalTE discuss a novel approach using hormone-filled microbeads in hydrogels for steady, extended release after monthly self-injections.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2026-03-11T14:00:00
Sponsored by Merck
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2023-03-23T14:46:21
Sponsored by Bio-Techne
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2023-05-10T11:18:16
Sponsored by Revvity
2023-11-20T13:43:43
Sponsored by Merck
Site powered by Webvision Cloud